AimedBio and Boehringer Ingelheim initiate Phase 1 study of ADC BI 4060107

CAR-T Digest - August 2020

Weekly Digest - October 2026

27 October 2026: AimedBio and Boehringer Ingelheim initiate Phase 1 study of ADC BI 4060107

AimedBio and Boehringer Ingelheim announced that the first patient has been dosed in the phase 1 trial of BI 4060107, an investigational ADC discovered by AimedBio and licensed to Boehringer Ingelheim for global development, in patients with advanced solid tumors. The milestone triggers a payment to AimedBio under their global collaboration and licensing agreement
The first-in-human phase 1 study is evaluating different doses of BI 4060107, with a primary focus on safety and tolerability. The amount of the milestone payment has not been disclosed; AimedBio is eligible to receive up to US$991 million in upfront, development, regulatory and commercial milestone payments, plus royalties
The program addresses the need for new targeted treatments in advanced solid tumors, where many patients lack precision treatment options and tumors can develop resistance to existing therapies
BI 4060107 is an investigational ADC developed using AimedBio’s proprietary P-ADC platform, which uses a patient-driven approach to identify and validate tumor-selective targets. The target has not been disclosed, but the companies describe it as highly expressed across multiple cancer types, minimally present in normal tissues and associated with tumor growth, metastasis and treatment resistance
Strategically, the first-patient dosing milestone advances BI 4060107 from discovery into clinical evaluation and validates AimedBio’s ability to generate ADC candidates for global development. For Boehringer Ingelheim, the program expands its oncology ADC pipeline with a potentially first-in-class candidate, while the milestone provides further financial returns under the 2025 licensing agreement